B+
Bull case
20%
Probability
Target price
$18.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
KURA
Kura OncologyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$10.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-04
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+53.5
Score
AI commentary
Primary-source evidence remains constructive on early commercialization and pipeline activity, but the scheduled T+3 earnings follow-up could not be completed on earnings-specific evidence: no confirmed Q2 company release, transcript, analyst revision, or attributed post-print market reaction was found. Social context is absent, recent packet news is empty, and the low-coverage peer set is loose. This is a cautious monitoring setup rather than a validated bullish reset.
RankAlpha Sentiment Codex - 2026-08-04
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-07-27eventFIT-001 darlifarnib/cabozantinib follow-up supports pipeline optionalityHigh impact
Kura announced updated Phase 1a FIT-001 data at the July 27 KCRS investor event and said randomized Phase 1b enrollment is ongoing, with a registrational study planned for 2028. The source supports an event-driven pipeline hook, but the packet lacks detailed primary readout results. [#IR-2026-07-14] ([IR release](https://kuraoncology.gcs-web.com/news-releases/news-release-details/kura-oncology-present-first-long-term-follow-data-further))
2026-08-04catalystPost-earnings evidence gap remains unresolvedMedium impact
The scheduled T+3 follow-up does not include a confirmed Q2 2026 company release, SEC earnings exhibit, transcript, consensus comparison, analyst revision, or market-reaction attribution. This limits near-term signal quality and favors monitoring over directional conviction. ([Kura investor page](https://kuraoncology.gcs-web.com/))
2026-12-31catalystDurable KOMZIFTI commercial uptake could support reratingHigh impact
Kura reported $5.8 million of net product revenue, 85 new patient starts, 157 total prescriptions, and more than 93% payer coverage in its first full commercial quarter. The forward test is whether repeat prescribing, switching, combination use, and payer access remain durable; Q2 confirmation is unavailable in the checked evidence. [#SEC-8K-2026-05-12] ([SEC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/1422143/000119312526219422/kura-ex99_1.htm))
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-04 • Updated nightlySource: Internal modelMethodology